JP2010511715A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511715A5
JP2010511715A5 JP2009540280A JP2009540280A JP2010511715A5 JP 2010511715 A5 JP2010511715 A5 JP 2010511715A5 JP 2009540280 A JP2009540280 A JP 2009540280A JP 2009540280 A JP2009540280 A JP 2009540280A JP 2010511715 A5 JP2010511715 A5 JP 2010511715A5
Authority
JP
Japan
Prior art keywords
neuromuscular
cysteine
composition
blocking agent
glutathione
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009540280A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511715A (ja
JP5213137B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/024914 external-priority patent/WO2008070121A1/en
Publication of JP2010511715A publication Critical patent/JP2010511715A/ja
Publication of JP2010511715A5 publication Critical patent/JP2010511715A5/ja
Application granted granted Critical
Publication of JP5213137B2 publication Critical patent/JP5213137B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009540280A 2006-12-06 2007-12-05 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト Active JP5213137B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87313206P 2006-12-06 2006-12-06
US60/873,132 2006-12-06
PCT/US2007/024914 WO2008070121A1 (en) 2006-12-06 2007-12-05 Intermediate duration neuromuscular blocking agents and antagonists thereof

Publications (3)

Publication Number Publication Date
JP2010511715A JP2010511715A (ja) 2010-04-15
JP2010511715A5 true JP2010511715A5 (OSRAM) 2011-02-03
JP5213137B2 JP5213137B2 (ja) 2013-06-19

Family

ID=39492558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009540280A Active JP5213137B2 (ja) 2006-12-06 2007-12-05 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト

Country Status (8)

Country Link
US (1) US8148398B2 (OSRAM)
EP (1) EP2101772B1 (OSRAM)
JP (1) JP5213137B2 (OSRAM)
CN (1) CN101588803B (OSRAM)
AT (1) ATE554769T1 (OSRAM)
AU (1) AU2007328210B2 (OSRAM)
CA (1) CA2671904C (OSRAM)
WO (1) WO2008070121A1 (OSRAM)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007328210B2 (en) 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
BRPI0808272A2 (pt) * 2007-03-08 2014-07-08 Chemagis Ltd "método para cromatograficamente separar o isômero 1r-cis, 1´r-cis de uma mistura de isômeros de (1r-1'r) - atracúrio, besilato de cisatracúrio e isômero 1r-cis, 1'r-cis do besilato de cisatracúrio"
EP2125743A1 (en) * 2007-03-26 2009-12-02 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
WO2008132748A1 (en) * 2007-05-01 2008-11-06 Chemagis Ltd. Process for producing cisatracurium compounds and associated intermediates
AU2008273724B2 (en) * 2007-05-01 2013-05-23 Chemagis Ltd. Process for Producing Cisatracurium and Associated Intermediates
WO2008155752A1 (en) * 2007-06-18 2008-12-24 Chemagis Ltd. (1r,1'r)-atracurium salts separation process
BRPI0812625A2 (pt) * 2007-07-09 2019-02-19 Chemagis Ltd processo para preparar um sal de cis-atracúrio
CA2702535A1 (en) * 2007-10-29 2009-05-07 Chemagis Ltd. Novel r,r'-atracurium salts
BRPI0907656A2 (pt) * 2008-05-01 2019-08-27 Chemagis Ltd composto para testar a pureza de cisatracúrio, método para testar a pureza de uma amostra de besilato de cisatracúrio, uso de um composto para testar a pureza de cisatracúrio e processo para preparar compostos para testar a pureza de cisatracúrio
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection
US9156826B2 (en) 2012-06-29 2015-10-13 Cornell University Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration
WO2014210369A2 (en) * 2013-06-28 2014-12-31 Cornell University Reversal of cysteine-inactivated neuromuscular blocking drugs with combinations of reversal agents
CN108375644B (zh) * 2016-12-07 2021-11-30 四川科瑞德制药股份有限公司 一种神经肌肉阻滞剂中间体的分析方法
CN110776481B (zh) 2018-07-24 2023-06-16 四川大学华西医院 一类双阳离子化合物及其制备方法和用途
CN108727248B (zh) 2018-07-25 2021-05-25 四川大学华西医院 一类双季铵化合物及其制备方法和用途
WO2021115413A1 (zh) * 2019-12-11 2021-06-17 江苏恒瑞医药股份有限公司 神经肌肉阻滞剂及其制备方法
JP7748737B2 (ja) * 2020-10-17 2025-10-03 コーネル・ユニバーシティー Ｎｍｂａ投与後の回復を制御および予測するための方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3004031A (en) 1958-07-03 1961-10-10 Allen & Hauburys Ltd Diquaternary salts of papaverino esters
US4036959A (en) * 1974-10-29 1977-07-19 Millmaster Onyx Corporation Microbiocidal capped polymers
AU506657B2 (en) * 1975-12-10 1980-01-17 Wellcome Foundation Limited, The Isoquinoline derivatives
US4039682A (en) * 1976-03-29 1977-08-02 Baxter Travenol Laboratories, Inc. Method and composition for relief of back pain
MC1197A1 (fr) * 1977-08-01 1979-03-19 Massachusetts Gen Hospital Composes tetrahydro-isoquinoleiniques myorelaxants(agents de blocage de la plaque neuro-musculaire)et leur preparation
US4192877A (en) * 1977-08-01 1980-03-11 Massachusetts General Hospital Neuromuscular blocking agents
US4235906A (en) * 1978-07-21 1980-11-25 Massachusetts General Hospital Bis-isoquinolinium compounds, compositions and methods of use
ATE921T1 (de) 1978-09-05 1982-05-15 Akzo N.V. Saeureadditionssalze von 2-beta, 16-beta-bis-piperidino-an drostan-16-beta-monoquaternaeren ammoniumderivaten und diese enthaltende pharmazeutische zusammensetzungen.
US4491665A (en) * 1979-10-19 1985-01-01 Burroughs Wellcome Co. Method of preparing isomers of bis isoquinolinium compounds
US4556712A (en) * 1981-05-20 1985-12-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation and racemization of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines
US4727146A (en) * 1980-07-03 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction
US4701460A (en) * 1980-12-17 1987-10-20 Burroughs Wellcome Co. Long duration neuromuscular blocking agents
GR79603B (OSRAM) * 1982-07-24 1984-10-31 Pfizer
BG38182A1 (en) * 1983-06-21 1985-11-15 Ivanova Tocolytic means
GB8418303D0 (en) * 1984-07-18 1984-08-22 Wellcome Found Compounds
DE3436179A1 (de) * 1984-10-03 1986-04-10 Merck Patent Gmbh, 6100 Darmstadt Verfahren zur herstellung optisch aktiver amine
GB8518634D0 (en) * 1985-07-23 1985-08-29 Smithkline Beckman Corp Chemical compounds
US5453510A (en) * 1990-07-13 1995-09-26 Burroughs Wellcome Co. Neuromuscular blocking agents
DE4135710A1 (de) * 1991-10-30 1993-05-06 Basf Ag, 6700 Ludwigshafen, De Cyclische ammoniumverbindungen und ihre verwendung als glanzmittel fuer waessrig-saure galvanische nickelbaeder
US5240939A (en) * 1991-10-31 1993-08-31 Anaquest, Inc. Nitrogen bridge tetrahydroisoquinolines
US5739170A (en) * 1992-09-11 1998-04-14 The Regents Of The University Of California Inhibitors of metazoan parasite proteases
US5684154A (en) * 1996-02-16 1997-11-04 Abbott Laboratories Process for the preparation and isolation of atracurium besylate
EP1526130A1 (en) 1997-03-25 2005-04-27 Avera Pharmaceuticals, Inc. Substituted isoquinolines as ultra short acting neuromuscular blockers
WO1998047534A1 (de) * 1997-04-18 1998-10-29 Klinge Pharma Gmbh Stabilisiertes arzneimittel enthaltend cysteinylderivate
US7897598B2 (en) * 1998-06-09 2011-03-01 Alexandros Makriyannis Inhibitors of the anandamide transporter
US6562836B1 (en) * 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
ATE367145T1 (de) * 1999-12-21 2007-08-15 Kao Corp Topische kosmetische und pharmazeutische mittel enthaltend spezifische alkoxilierte diester der fumarsäure
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
US7763263B2 (en) * 2000-03-30 2010-07-27 Kao Corporation Skin external agents and drugs
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
SK288238B6 (sk) * 2001-01-12 2015-01-07 Fumapharm Ag Amidy kyseliny fumarovej
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
KR101153250B1 (ko) * 2003-08-12 2012-06-05 니폰 조키 세야쿠 가부시키가이샤 글리시리진 고농도 제제
US20050192243A1 (en) * 2003-10-28 2005-09-01 Savarese John J. Neuromuscular blocking agents and antagonists thereof
EP1965763B1 (en) * 2005-12-27 2019-11-06 Ramot at Tel Aviv University Ltd. Stable enzymatic preparations and methods of use thereof
AU2007328210B2 (en) 2006-12-06 2012-11-22 Cornell Research Foundation, Inc. Intermediate duration neuromuscular blocking agents and antagonists thereof
WO2010107488A1 (en) * 2009-03-17 2010-09-23 Cornell University Reversible nondepolarizing neuromuscular blockade agents and methods for their use
US9220700B2 (en) * 2009-08-19 2015-12-29 Cornell University Cysteine for physiological injection

Similar Documents

Publication Publication Date Title
JP5213137B2 (ja) 中程度の持続時間の神経筋遮断剤およびそのアンタゴニスト
JP2010511715A5 (OSRAM)
RU2673081C1 (ru) Сочетанные препараты неосакситоксина для пролонгированной местной анестезии
Oxorn et al. Bolus doses of esmolol for the prevention of perioperative hyper-tension and tachycardia
US20110166220A1 (en) Dronedarone for the prevention of permanent atrial fibrillation
Avramov et al. Effects of nicardipine and labetalol on the acute hemodynamic response to electroconvulsive therapy
EA028060B1 (ru) Комбинированная терапия бокового амиотрофического склероза
KR20210139293A (ko) 폐동맥 고혈압 및 연관 폐동맥 고혈압 치료방법 및 매일 투여
EP3678643B1 (en) Sublingual epinephrine tablets
Takahashi et al. Naloxone reversal of opioid anesthesia revisited: clinical evaluation and plasma concentration analysis of continuous naloxone infusion after anesthesia with high-dose fentanyl
Shao et al. Treatment of infantile hemangioma by intralesional injection of propranolol combined with compound betamethasone
CN108939052B (zh) 艾塞那肽在制备预防或治疗房颤的药物中的用途
EP3019169A1 (en) Hydroxychloroquine for the treatment of cardiovascular disease
Meyendorff et al. Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment
WO2005041960A2 (en) Neuromuscular blocking agents and antagonists thereof
Frishman et al. Ultra-short-acting β-adrenergic blockers
JPH03505447A (ja) アミオダロンと、ニトロ誘導体、特にイソソルビト二硝酸と、必要に応じてさらにβ―遮断薬とを含む心臓保護効果のある医薬組成物
Komori et al. Antiarrhythmic effect of magnesium sulfate against occlusion-induced arrhythmias
ES2483940T3 (es) Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano
Jamidar et al. Nalbuphine versus diamorphine early in the course of suspected myocardial infarction
Farkash et al. HAND/PERIPHERAL NERVE
JP6935930B2 (ja) 生薬成分を含む肺高血圧症の予防又は治療剤
Haque et al. Epinephrine in Paediatric Clinical Practice-Clinical Update
Gupta et al. Comparative evaluation of a mixture of atracarium and tramadol or ketorolac as an adjunct to low dose lignocaine in intravenous regional anesthesia
CN115068476A (zh) 几种治疗心力衰竭的组合药物及其用途